Skip to content

Condition hub

Living with igg4-related disease

What IgG4-related disease is, why a scan of it so often looks like cancer at first, and why just one paper out of 167 could serve as a care guideline.

Free download

The First Changes to Make.

The same handout I hand my own patients: the specific food and daily-exposure changes worth making first, no guesswork required.

No spam · Unsubscribe any time
Quick answerIn IgG4-related disease, immune cells crowd into an organ and cause swelling, scar tissue, and a slow loss of function. It usually answers well to steroids, which is one of its clearest features. A search read 167 papers looking for a care guideline and found one, and no treatment rules rest on good trials yet.
This illness is worth learning about because it copies cancer. It makes lumps in the pancreas, the bile ducts, the spit glands, and other places, and on a scan those lumps can look like tumors. Telling them apart takes a tissue sample and the whole clinical picture rather than the scan alone. Getting it right counts both ways, because treating this illness as cancer means surgery that was never needed, and calling a cancer this illness puts cancer care off. That's why the tissue sample counts for so much here.

What IgG4-related disease does, and why a scan of it looks like cancer.

Immune cells crowd into an organ

They pile into the tissue and cause swelling, scar tissue, and a slow loss of what that organ does. The pancreas, the bile ducts and the spit glands are common sites, and more than one organ is often involved at once.

The lumps look like tumors

On a scan a crowd of immune cells and a tumor can look alike, which is why cancer gets suspected first and why the work-up runs slower than a swelling problem seems to deserve. Only a tissue sample tells the two apart.

It usually answers to steroids

That fast answer is one of its clearest features and part of how the diagnosis gets supported. It also comes with everything a long steroid course brings, which is why bone, blood sugar and blood pressure belong in the plan from the start.

The guidance is thin, and that is measured

A review screened 167 papers looking for something usable as a care guideline and found one, a consensus statement written by experts across several specialties. No shared rules for sorting cases exist, and no score exists for how active the illness is.1

The four-step plan, applied to IgG4-related disease.

  1. Get the right diagnosis

    A tissue sample and the whole clinical picture, because a scan alone will not separate this from cancer. A raised IgG4 level in the blood supports the picture without making the diagnosis on its own.

    IgG4-related disease and labs →
  2. Clean up your food

    No diet has been tested in this illness at all. Which organ is involved decides what your food problem is, so pancreas or bile duct involvement changes how you absorb what you eat and is worth raising directly.

    IgG4-related disease and diet →
  3. Detox your daily life

    No exposure has been measured in this illness either, so anything you read about causes here came from somewhere else. The steroid course is the exposure with real evidence behind it.

    IgG4-related disease and environment →
  4. Build a stronger body

    There is no program written for this illness, so the honest starting point is what you can do now. Weight-bearing and strength work is what the steroid guideline asks for, and that guideline does cover you.

    IgG4-related disease and exercise →

Pro tip

Ask which organ is involved in your own case and write the answer down. This illness looks completely different depending on where it settles, so the monitoring, the food problems and the symptoms worth mentioning all follow from that one answer, and you may be the only person who sees the whole picture across the specialties involved.

Why cancer gets suspected first

The single most important thing to know is that this illness makes lumps that look like tumors. Two of the places it commonly settles are the pancreas and the bile ducts, and both are in territory where cancer is a real and time-critical risk. No doctor looking at those organs can assume the safe answer.

Getting it right counts in both directions at once. Treat IgG4-related disease as cancer and somebody has surgery they never needed, and call a cancer this illness and cancer care gets put off when it shouldn't wait. That two-sided risk is why the tissue sample counts for as much as it does.

Why the guidance is so thin

Treatment

Steroids are the usual starting point and this illness usually answers to them well, which is one of its clearest features. What happens after that is less settled, because keeping it quiet over years is where the evidence thins out. That is also where practice varies most between one team and another.

A drug trial published in 2026 is the first large piece of real evidence here, and it is worth knowing that it exists at all. Ask your own team what it changes for you, because a trial result and a treatment decision are two different things. The second one belongs to the doctor who knows your case and your other conditions.

Go deeper.

IgG4-related disease and diet

Read →

IgG4-related disease and exercise

Read →

IgG4-related disease and environment

Read →

IgG4-related disease and blood tests

Read →

IgG4-related disease case studies

Being written

IgG4-related disease: common questions

Read →

When to see a rheumatologist.

See a rheumatologist if you have:

  • A tumor-like mass in pancreas, salivary glands, orbit, or retroperitoneum that's puzzling on imaging
  • Persistent salivary gland or lacrimal gland enlargement
  • Autoimmune pancreatitis
  • Unexplained retroperitoneal fibrosis
  • Orbital pseudotumor
  • Elevated serum IgG4 level on a routine lab
  • Multiple organ involvement of unclear cause

A puzzling tumor-like mass, glands that stay swollen, or a raised IgG4 level on a routine blood test are the usual routes in. The weeks of being checked for cancer are doing real work even when they feel like nothing but delay, because treating this as cancer and missing a cancer are both real risks.

References.

  1. Iaccarino L; Talarico R; Scirè C et al. IgG4-related diseases: state of the art on clinical practice guidelines. RMD Open. 2019;4:e000787. 10.1136/rmdopen-2018-000787Systematic literature review for clinical practice guidelines in IgG4-related disease
  2. Della-Torre E; Baker MC; Zhang W et al. Obexelimab for the Treatment of IgG4-Related Disease. N Engl J Med. 2026. 10.1056/NEJMoa2601337Phase 3
  3. Tanaka Y; Umehara H; Sato H et al. Inebilizumab treatment in Japanese patients with IgG4-related disease: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE). Mod Rheumatol. 2026;36:801-808. 10.1093/mr/roag020Prespecified subgroup analysis of MITIGATE

This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.